|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.54 - 27.79|
|52 Week Range||27.41 - 34.52|
|PE Ratio (TTM)||21.06|
|Forward Dividend & Yield||1.08 (3.87%)|
|1y Target Est||N/A|
Roche’s (RHHBY) Tarceva generated revenues of 141 million Swiss francs in the first quarter compared to 211 million Swiss francs in the first quarter of 2017, which reflected an ~32% YoY (year-over-year) CER (constant exchange rate) decline and a 31% sequential decline.
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.
Roche’s (RHHBY) Xolair generated revenues of 442 million Swiss francs in the first quarter compared to 437 million Swiss francs in the first quarter of 2017, which reflected ~1% YoY (year-over-year) growth and ~3% growth sequentially. In the US market, Roche commercializes Xolair while Novartis commercializes it outside the US market. In the first quarter, Novartis (NVS) reported revenues of $255 million from the sales of Xolair, which reflected ~14% YoY growth.
Swiss private bank and asset manager Vontobel (VONN.S) is buying private bank Notenstein La Roche from Swiss cooperative bank Raiffeisen [RFSHW.UL] for 700 million Swiss francs ($705 million), the two parties said on Thursday. "Notenstein La Roche perfectly complements the strong organic growth we have achieved in wealth management over a number of years," Vontobel Chief Executive Zeno Staub said in a statement.
In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs, which included revenues of 18 million Swiss francs from the US market and 5 million Swiss francs from the European market.
Roche’s (RHHBY) Tecentriq (atezolizumab), a PD-L1 blocker is approved for use in the treatment of individuals with metastatic urothelial carcinoma in patients. These patients would not be eligible candidates for cisplatin-containing chemotherapy, or showed disease progression after treatment with platinum-containing chemotherapy.
In the first quarter, Roche’s (RHHBY) Tecentriq generated revenues of 139 million Swiss francs compared to 113 million Swiss francs in the first quarter of 2017, which reflected ~29% year-over-year (or YoY) CER (constant exchange rate) growth. In the US market, Tecentriq witnessed ~5% YoY growth in the first quarter.
In the first quarter, Roche’s (RHHBY) Ocrevus generated revenues of 479 million Swiss francs compared to 369 million Swiss francs in the fourth quarter of 2017, which reflected ~30% sequential growth.
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.
Roche Holding AG (SWX:ROG) is currently trading at a trailing P/E of 22.2x, which is lower than the industry average of 24.8x. While ROG might seem like an attractive stockRead More...
Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.
Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.
Roche’s (RHHBY) Herceptin reported revenues of 1.77 billion Swiss francs in the first quarter compared to 1.76 billion Swiss francs in the first quarter of 2017, which reflected ~2.0% YoY (year-over-year) growth at constant exchange rates. In the fourth quarter of 2017, Herceptin reported revenues of 1.78 billion Swiss francs, which reflects a flat revenue trend compared to the first quarter.
Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.
In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.
Roche's new haemophilia drug Hemlibra dramatically reduced bleeding in a broad population of haemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position. Hemlibra cut by 96 percent the incidence of treated bleeds in haemophilia A patients who did not get preventive treatment, and compared with patients who did get preventive treatment in the form of clotting factors it reduced them by 68 percent. The positive results from the two trials known as HAVEN 3 and 4 included so-called non-inhibitor patients.
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.
Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.
The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.
For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.
Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. Herceptin, a biotech medicine that costs around $76,700 a year in the United States, generated 2017 worldwide sales of more than $7 billion for Roche. If a shorter treatment duration is widely adopted it could significantly reduce sales.
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.